Ibrahim Y. A.
- Country
- France
- Department
- Unité de Thérapie Cellulaire – Service des Maladies du Sang
Research Overview
- Phase 1 Evaluation of CD19-Targeted Allogeneic CAR T Cells in Severe Refractory Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Idiopathic Inflammatory Myopathy
- Long-term Follow-up of Gene-Modified Cell Therapy with Brexucabtagene Autoleucel and Axicabtagene Ciloleucel in Solid and Hematological Malignancies
- Phase 2 Multicohort Open-Label Study of Ciltacabtagene Autoleucel CAR-T Therapy Targeting BCMA in Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 64 of 131 partner sites.
Specializations
Cell Therapy Innovation
This investigator specializes in CAR T-cell therapy applications across multiple therapeutic areas, with particular emphasis on both hematologic and neurological conditions.
- Multiple Sclerosis Treatment Innovation
- Myasthenia Gravis Therapy
- Hematological Malignancies
Their work encompasses both relapsing and progressive forms of multiple sclerosis, demonstrating expertise in autoimmune neurological conditions.
Oncology Focus
The investigator conducts research in targeted cellular therapies for various blood cancers, including specialized work in:
- Acute Myeloid Leukemia
- Multiple Myeloma
- CD19-targeted Therapies
Their research includes novel approaches to minimal residual disease assessment in blood cancers.
Long-term Safety Monitoring
The investigator leads comprehensive long-term follow-up studies of patients treated with cellular therapies, focusing on:
- Delayed Adverse Event Assessment
- Pediatric Patient Monitoring
- Gene-Modified Cell Persistence
Their work includes monitoring both adult and pediatric populations for long-term therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.